Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4232151 | 0.98 | KMT2A (0.47) | KMT2AGLAMGAMGAASI | |
| Hydrochloric Acid SCHEMBL624259 | 0.96 | KMT2A (0.46) | KMT2AGLAMGAMGAASI | |
| SCHEMBL8968502 | 0.84 | GLA (0.44) | KMT2AGLAMEN1ERAP1ALDH1A1 | |
| SCHEMBL25583582 | 0.83 | GAA (0.48) | KMT2AGLAMGAMGAASI | |
| SCHEMBL19037385 | 0.81 | KMT2A (0.45) | KMT2ATDP1MEN1ALDH1A1KDM4E | |
| Bromide SCHEMBL18554709 | 0.81 | KMT2A (0.47) | KMT2AGLAMEN1ALDH1A1KDM4E | |
| Bromide SCHEMBL9243928 | 0.81 | ALDH1A1 (0.47) | KMT2AGLAMGAMGAASI | |
| Bromide SCHEMBL16100576 | 0.81 | KMT2A (0.45) | KMT2AGLAMGAMGAASI | |
| Bromide SCHEMBL9080240 | 0.79 | KMT2A (0.53) | KMT2AMEN1ALDH1A1KDM4EHTT | |
| Bromide SCHEMBL11204407 | 0.79 | PABPC1 (0.59) | KMT2AGLAALDH1A1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0548348-B1 | TONERS AND DEVELOPERS CONTAINING ESTER-CONTAINING QUATERNARY PYRIDINIUM SALTS AS CHARGE CONTROL AGENTS | EASTMAN KODAK CO (US) | 1996-03-20 | — | — | EP | claimed |
| EP-0548348-A1 | TONERS AND DEVELOPERS CONTAINING ESTER-CONTAINING QUATERNARY PYRIDINIUM SALTS AS CHARGE CONTROL AGENTS. | EASTMAN KODAK CO (US) | 1993-06-30 | — | — | EP | claimed |
| WO-1993002397-A1 | TONERS AND DEVELOPERS CONTAINING ESTER-CONTAINING QUATERNARY PYRIDINIUM SALTS AS CHARGE CONTROL AGENTS | EASTMAN KODAK COMPANY (US) | 1993-02-04 | — | — | WO | claimed |
| WO-1993002053-A1 | ESTER-CONTAINING QUATERNARY PYRIDINIUM SALTS | EASTMAN KODAK COMPANY (US) | 1993-02-04 | — | — | WO | claimed |
| EP-3070087-B1 | INTERMEDIATES FOR THE SYNTHESIS OF CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-31 | — | — | US | disclosed |
| US-9951071-B2 | Dihydropyridone P1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-24 | — | — | US | disclosed |
| US-9902742-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170158712-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2739628-B1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9611274-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-04 | — | — | US | disclosed |
| EP-1601678-A2 | FUSED PYRROLE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050014754-A1 | Fused pyrrole compounds | SYNTA PHARMACEUTICALS CORP. | 2005-01-20 | — | — | US | disclosed |
| WO-2004082606-A2 | FUSED PYRROLE COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2004-09-30 | — | — | WO | disclosed |
| EP-0548348-B1 | TONERS AND DEVELOPERS CONTAINING ESTER-CONTAINING QUATERNARY PYRIDINIUM SALTS AS CHARGE CONTROL AGENTS | EASTMAN KODAK CO (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0548348-A1 | TONERS AND DEVELOPERS CONTAINING ESTER-CONTAINING QUATERNARY PYRIDINIUM SALTS AS CHARGE CONTROL AGENTS. | EASTMAN KODAK CO (US) | 1993-06-30 | — | — | EP | disclosed |
| US-5196538-A | Electrography | EASTMAN KODAK COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| WO-1993002397-A1 | TONERS AND DEVELOPERS CONTAINING ESTER-CONTAINING QUATERNARY PYRIDINIUM SALTS AS CHARGE CONTROL AGENTS | EASTMAN KODAK COMPANY (US) | 1993-02-04 | — | — | WO | disclosed |
| WO-1993002053-A1 | ESTER-CONTAINING QUATERNARY PYRIDINIUM SALTS | EASTMAN KODAK COMPANY (US) | 1993-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | KMT2A 1182/4885GLA 1248/4885MGAM 2145/4885 |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | TFPI, TFPI2, F12 | KMT2A 1029/4885GLA 977/4885MGAM 1829/4885 |
| US-20050014754-A1 | Fused pyrrole compounds | PDE4A, PDE4B, IL4 | KMT2A 2890/4885GLA 2358/4885MGAM 4212/4885 |
| US-20170158712-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | KMT2A 1182/4885GLA 1248/4885MGAM 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.